Share Twitter LinkedIn Facebook Email Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke"™s Medical Center, offers opinion on the most promising studies in multiple myeloma (MM) presented at ASH 2019.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read